Complement activation in patients with isolated antiphospholipid antibodies and primary antiphospholipid syndrome (PAPS) : 1
Heparin-induced thrombocytopenia (HIT): evaluation of soluble platelet glycoprotein VI as a biomarker for HIT : 2
Fibrinogen replacement for major haemorrhage in trauma - an in-vitro study : 3
Management and outcomes in women with late obstetric morbidity associated with a thrombotic basis : 4
Lupus anticoagulant guidelines: how far have these been adopted by laboratories? : 5
Development and application of a new automated thrombin generation assay that is sensitive to activated protein C resistance : 6
Are circulating endothelial cells increased in patients with venous thromboembolism and are levels greater in patients with underlying malignancy and venous thromboembolism? : 7
Identification and characterization of a novel inborn error of folate metabolism causing megaloblastic anemia, pancytopenia neurodevelopmental delay and seizures : 8
High incidence of asymptomatic osteonecrosis during treatment for childhood acute lymphoblastic leukaemia : 9
Late cardiotoxicity in survivors of the paediatric arm of MRC AML 12 : 10
Global gene expression analysis of human erythroid progenitors : 11
Measured levels of maternal HPA-1a antibody vary depending on the conformation and density of integrin β3 : 12
Regulation of Trib2 gene expression in normal and AML cells : 13
Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma : 14
Adult T-cell leukaemia/lymphoma (ATLL) in England 1999–2009 - use of zidovudine and interferon-alpha with chemotherapy improves survival : 15
NCRN CLL207 study of alemtuzumab consolidation in chronic lymphocytic leukaemia: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group) : 16
B cell-activating factor (BAFF) is elevated in acute idiopathic thrombotic thrombocytopenic purpura (TTP) : 17
p53 is induced in human T cells during entry into the cell cycle and when bound to DNA, p53 protein complexes contain MDM2, p68-DDX5 and ΔNp73 : 18
Neonatal alloimmune thrombocytopenia (NAIT): unusual presentations and regional variations in referral : 19
Safety of PEX in the treatment of thrombotic thrombocytopenia purpura (TTP) patients : 20
Audit of the transfusion management of major blood loss in the emergency department of a UK teaching hospital : 21
A multicentre prospective observational survey of the perioperative use of blood components in paediatric cardiac surgery : 22
National comparative audit of the use of red cells in neonates and children : 23
Frequency of red cell antibody alloimmunization in patients with sickle cell disease at Muhimbili National Hospital, Dar-es-Salaam, Tanzania : 24
Development of an ELISA based screening test for anti-malarial antibodies : 25
One year of real-time radiological data of venous thromboembolism (VTE) events in a large teaching hospital : 26
CCN3 counteracts malignant features in chronic myeloid leukaemia : 27
Over-expression of the erythropoietin receptor (EpoR) in TEL-AML1 positive acute lymphoblastic leukaemia : 28
5-aza-2′-deoxycytidine, a DNA methylation inhibitor, induces miRNA expression changes in acute myeloid leukaemia cell lines that transcend subtype : 29
Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease : 30
The cyclin-dependent kinase inhibitor CR8 targets proliferating chronic lymphocytic leukaemia cells revealing a discrete chemo-resistant, non-dividing population : 31
Different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells : 32
Modulation of PKCα induces an upregulation of PKCβII and cyclin D1 in a chronic lymphocytic leukaemia mouse model : 33
Gaucher derived mono-layers prime myeloma cells for survival against chemo-therapeutic agents : 34
Video-assisted thoracoscopic (VATS) biopsy is feasible and safe in adult haemato-oncology patients undergoing stem cell transplantation or high dose chemotherapy : 35
High C-reactive protein levels predict poor prognosis in reduced intensity conditioning allogeneic stem cell transplants : 36
Rationalising strategies to prevent cytomegalovirus disease in recipients of T cell depleted allogeneic haemopoietic stem cell transplants (HSCT): identification of a subset of patients who reactivate but can be safely monitored : 37
Cardiovascular risk factors in long-term survivors of stem cell transplantation for haematological malignancy : 38
Major ABO mismatch is associated with increased non-relapse mortality in alemtuzumab-conditioned unrelated donor allogeneic haematopoietic stem cell transplantation : 39
Therapeutic drug monitoring of itraconazole and posaconazole : 40
Application of a new strategy to identify regulators of a signalling pathway in human immune cells : 41
Separation of cell cycle and growth cycle programmes in primary human T cells : 42
Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL). : 43
Outcome prediction in solitary plasmacytoma of bone: development of a risk stratification model utilising bone marrow flow cytometry and light chain analysis : 44
The outcome for elderly patients with diffuse large B cell lymphoma achieving partial response or relapsing at least a year after first-line therapy warrants consideration of aggressive salvage : 45
Atypical BCR-ABL1 transcript types in adult Ph-positive acute lymphoblastic leukaemia : 46
Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma : 47
International phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom macroglobulinaemia and related disorders : 48
Eculizumab is an effective treatment for patients with atypical hemolytic syndrome (aHUS) receiving chronic plasma therapy (PT) : 49
Improving the immediate management of neutropenic sepsis in the United Kingdom: lessons from a national audit : 50
Simultaneous t(5;11)(q35;p15) NUP98-NSD1 gene fusion and FLT3-itd in paediatric acute myeloid leukaemia : 51
Treatment outcomes in a cohort of patients with Castleman's disease : 52
Blood film examination in Malawi - the maximum diagnostic information for the least resources? : 53
Long term treatment with eculizumab in paroxysmal nocturnal haemoglobinuria (PNH): sustained efficacy and improved survival : 54
Paroxysmal nocturnal haemoglobinuria reveals a role for glycosylphosphatidylinositol-linked molecules in the function and peripheral homeostasis of human NK cell subsets : 55
Low risk of stroke in children with sickle cell disease (SCD) screened with transcranial Doppler (TCD) ultrasound : 56
Neonatal screening for haemoglobinopathies at Muhimbili National Hospital, Dar es Salaam. A pilot study : 57
Mortality in sickle cell anaemia in Africa: rates and risk factors from a prospective cohort study in Tanzania : 58
A haemato-neurological disease caused by mutations in SLC2A1, coding for the GLUT1 glucose transporter : 59
Rituximab therapy for immune mediated haematological disorders: a retrospective study of the experience in Scotland on behalf of the Haematology Audit Group in Scotland (HAGIS) : 60
Molecular analysis of putative bipotential precursors of B cells and macrophages in murine foetal liver using single-cell RT-PCR cDNA subtraction : 61
A prospective audit of the impact of general practitioner full blood count requests on clinical haematology workload: a London teaching hospital experience : 62
HbA2 estimations in UK National External Quality Assessment data indicate a degree of bias and the need for harmonisation of methods : 63
An audit comparing a new intravenous (IV) iron preparation, ferric carboxymaltose (Ferinject) to IV iron dextran (Cosmofer) for the treatment of iron-deficiency anaemia in pregnancy : 64
The use of immature platelet fraction in differentiating between aeitiologies of thrombocytopenia : 65
An open label study for the assessment of response to oral ferrous salt supplement in the treatment of iron deficiency anemia in predominantly cereal diet based Indian patients : 66
Dar-Oxford-London link for health: providing postgraduate haematology training (MMed and MSc in haematology) : 67
Changes in primary care access patterns to consultant haematologist advice following the introduction of a direct GP telephone haematology advice service in a district general hospital : 68
Raised APTT in hospitalised patients with renal impairment: causes and association with low molecular weight heparin (LMWH) in a cohort of district general hospital in-patients : 69
Above range INR results on warfarin in a cohort of patients attending a district general hospital and review of point of care testing in response to NPSA 18 : 70
Heritability of vitamin B12 deficiency in seropositive pernicious anaemia : 71
Chala chimodzi sichiswa nsabwe* - What use is a haematologist in Malawi? : 72
Efficacy of low-dose rituximab for the treatment of refractory autoimmune cytopenias in adults : 73
Retrospective audit of the initial management of neutropenic sepsis at a district general hospital : 74
Venous thrombo-embolism prophylaxis in haematology patients : 75
Evaluation of the completeness of national haematological malignancy registration: comparison of national data with a specialist population-based register : 76
Thrombocytopenia in the Indian population - an interesting observation : 77
High early mortality associated with severe anaemia in HIV positive adults in Blantyre, Malawi: is there a possibility for intervention? : 78
In known sickle cell patients this audit investigates the time taken to administer an appropriate potent analgesic and whether, in a febrile patient (temperature > 38°C), appropriate investigations are initially carried out : 79
Is the 2 week wait target for cancer referrals for haematology working? : 80
Reduction in blood transfusion requirements following treatment of immune thrombocytopenic purpura with romiplostim : 81
Digital morphology:the UK National External Quailty Assessment Scheme for General Haematology Workshop : 82
Toxicity during induction chemotherapy for acute leukaemia - a single institute study : 83
Improving the assessment of peripheral neuropathy in patients receiving bortezomib (velcade) treatment for multiple myeloma : 84
Preventing venous thromboembolism: bridging the gap between theory and practice : 85
“Don't keep me hanging on the telephone!” : 86
Haematopoietic progenitor cell collection: smoothing the process : 87
Fanconi's anaemia like clinical syndrome without increased chromosomal breakages : 88
Paradoxical inhibition of the haemoglobin scavenging mechanism in sickle cell disease : 89
Spectrum of mutations in thalassemia major and thalassemia intermedia in north Indians : 90
Neurological events and abnormalities in SCD cohort in Tanzania : 91
The prevalence of hypovitaminosis D in sickle cell disease : 92
Primary care vaccination and antibiotic prophylaxis in patients with sickle cell disease: auditing NCEPOD recommendations : 93
The haemoglobinopathy associated mutation spectrum in the North West of England - the application of a non-selective versus ethnic led analysis strategy : 94
Use of fresh blood for transfusion of adult beta thalassaemic patients : 95
Are shortages of O RhD negative red cells avoidable? Results of the 2010 National Comparative re-audit of the use of group O RhD negative red cells : 96
Improving the efficient use of platelet transfusions in critically ill patients with decision support integrated into the electronic patient record : 97
Perceived hazards of blood transfusion: can a clinician tool improve a patient's understanding? : 98
Where are we regarding the management of major bleeding? : 99
Introduction of patient identification guidelines and identity wristbands in Queen Elizabeth Hospital, Blantyre, Malawi : 100
Clinical use of platelet auto-antibody testing - a prospective audit : 101
Ferritin, serum iron levels and total iron binding capacity in the multiple transfused adult patient with sickle cell anaemia at Benin, Nigeria : 102
Long term survival report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory chronic lymphocytic leukaemia : 103
The assessment of minimal residual disease in chronic lymphocytic leukaemia: comparison of multi colour flow cytometry and bone marrow trephine biopsy : 104
The addition of cyclophosphamide to bortezomib improves response rate but not time to next treatment: five year experience of bortezomib for myeloma in a regional cancer network : 105
Survey of breast screening in long-term survivors treated with supra-diaphragmatic irradiation for lymphoma : 106
UK experience of Ofatumumab in refractory B-CLL : 107
Bortezomib treatment in relapsed myeloma; effect of side effects on delivery of treatment cycles, responses and outcomes in actual clinical practice : 108
FDG-PET/CT staging in follicular lymphoma: effect on FLIPI score : 109
Real life experience of lenalidomide in multiple myeloma: Southwest Peninsula cancer network : 110
Imaging in the staging of myeloma : 111
Discharging survivors of good prognosis diffuse large B cell lymphoma : 112
Rituximab and dexamethasone in chronic lymphatic leukaemia : 113
Is an autologous stem cell transplant still effective salvage treatment for diffuse large B cell lymphoma in the era of upfront rituximab plus chemotherapy? An audit of outcomes from a single centre : 114
Rate limiting steps in the process of timely lymphoma diagnosis : 115
A 1-year experience of lymphoma diagnosis and management in rural Zambia : 116
Reducing complication rates and increasing diagnostic yield of splenic core biopsies using fibrin glue tract sealing : 117
Monocytoid B-cell leukaemia: a rare manifestation of probable nodal marginal zone lymphoma : 118
Investigation of mediastinal lymphoma : 119
R-CHOP chemotherapy is well tolerated and effective in elderly patients with diffuse large B cell lymphoma : 120
Post transplantation lymphoproliferation disorder (PTLD) following liver transplantation: a single center experience : 121
Prognostic significance of oligoclonal bands and excess bone marrow B lymphocytes in patients with multiple myeloma : 122
Investigation and follow up of newly identified M-proteins - a large DGH experience : 123
A unique case of ALK positive anaplastic large cell lymphoma initially presenting with a spontaneous leukaemic regression : 124
Rapid diagnosis of chronic myeloid leukaemia by flow cytometric detection of BCR-ABL1 protein : 125
Shared care protocol for the management of essential thrombocythaemia patients in primary care : 126
Therapy related myelodysplastic syndrome and acute myeloid leukaemia (tMDS/tAML) in patients treated with purine analogues (PA) for lymphoproliferative disorders (LPD); an update : 127
Efficient detection of Aspergillus DNA from broncho-alveolar lavage fluid of infected acute leukaemia patients : 128
Audit of the use and response rate of bortezomib in clinical practice: a UK retrospective observational study : 129
Evaluation of aetiology of hepatic dysfunction and its short term impact on mortality in patients of acute leukaemia during treatment. : 130
A rare case of inherited cytopenias with dysplastic features : 131
Oral P32 is an effective and easily administered therapy in myeloproliferative neoplasms : 132
Chronic myeloid leukaemia (CML) audit and review of clinical experience with tyrosine kinase inhibitors (TKI) (C.A.R.C.E.T): a population based study of the management of chronic myeloid leukaemia in Leicester : 133
Adverse effects of hydroxycarbamide are more prevalent in persons older than 60 years in essential thrombocythaemia : 134
Late toxicity of imatinib mesylate during therapy for chronic myeloid leukaemia (CML): what happens if you stop imatinib? : 135
Remission induction with low dose oral melphalan in acute myeloid leukemia and refractory anaemia with excess blast with normal cytogenetics and hypocellular marrow relapsing following intensive chemotherapy : 136
All-trans retinoic acid differentiation syndrome occurring in a patient with non-promyelocytic acute myeloid leukaemia : 137
Successful use of combination treatment with cidofovir, cytarabine and mirtazapine in a case of progressive multifocal leucoencephalopathy (PML) : 138
Characterization of acute promyelocytic leukaemia [APML] lacking the t(15;17) with underlying PML/ RARA rearrangement : 139
An investigation of the role of interleukin-15 in the growth and survival of pre-B acute lymphoblastic leukaemia cell lines : 140
Homing to the central nervous system is associated with differential expression of selectins, integrins and chemokine receptors in pre-B acute lymphoblastic leukaemia cell lines : 141
Haematopoietic stem cell kinetics in children after chemotherapy : 142
Management of acute leukaemia relapse post paediatric allograft transplant in the last decade: a single centre experience : 143
The spectrum and variability of the haematological phenotype of severe congenital neutropenia type 4 : 144
Cardiovascular features in severe congenital neutropenia type 4 : 145
Clinical features and outcome of paediatric thrombosis over 5 years: results from a UK regional registry : 146
Development of a paediatric home-based bleeding score : 147
Management of over-anticoagulation in children: a single-centre experience : 148
A review of clostridium difficile associated diarrhoea (CDAD) in a tertiary paediatric haematology/oncology centre : 149
Arginine to ornithine ratios in Tanzanian sickle cell anaemia patients at steady-state: a nested case control of deaths versus survivors : 150
Brain T2-weighted signal intensity ratio in children with sickle cell disease with and without stroke : 151
Iron status and nocturnal oximetry in Tanzanian paediatric sickle cell anaemia patients : 152
Percutaneous endoscopic gastrostomy feeds in children with sickle cell disease and growth failure; a novel approach with high patient and carer satisfaction : 153
Prevalence and acquired causes of anaemia in children admitted to Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania : 154
The burden and determinants of anaemia in HIV infected children attending public hospitals in Dar es Salaam : 155
An audit of a transfusion algorithm for use in paediatric thalassaemia patients : 156
3 year experience of deferasirox in a small paediatric cohort of beta thalassaemia major patients : 157
Use of short term hydroxycarbamide and once weekly erythropoietin to avoid transfusion in children with sickle cell anaemia undergoing adenotonsillectomy : 158
Treg GMP isolation for clinical trial in haematopoietic stem cell transplantation: lessons and experience : 159
Production of TNFα discriminates activated human Th cells from Treg cells : 160
Umbilical cord blood transplantation (UCBT) in teenagers and adults: Sheffield experience 2005–2010 : 161
Endocrine complications of stem cell transplantation for haematological malignancy : 162
The pMHC array demonstrates that untouched T cell populations from presentation myeloid leukaemia patients can recognize multiple tumour antigens : 163
Detailed molecular screening of an atypical CML reveals an unexpected ETV6-ABL1 fusion transcript : 164
Risk stratification of AML patients using prognostic markers NPM1 and FLT-3 in relation to WT1 status : 165
CD160: a novel approach to minimal residual disease (MRD) assessment in chronic lymphocytic leukaemia (CLL) : 166
Chronic lymphocytic leukaemia lymph node T-cells show evidence of chronic antigenic stimulation : 167
IgM ligation triggers Zeta associated protein of 70 kDa (ZAP-70) tyrosine 292 and 319 phosphorylation in B-Chronic lymphocytic leukaemia (B-CLL) : 168
Methylseleninic acid (MSA) is an HDAC inhibitor and suppresses VEGF production in lymphoma cell lines : 169
Effect of parthenolide on acute lymphoblastic leukaemia initiating cell populations : 170
Evaluation of the Illumina Human CytoSNP-12 BeadChip for the detection of cytogenetic abnormalities associated with B-cell chronic lymphocytic leukaemia on archival smears, using FISH as a comparative technique : 171
Age is associated with increased D-dimer levels, Wells score and imaging referrals in patients with suspected deep vein thrombosis : 173
Day case surgery: who should receive pharmacological thromboprophylaxis - local practice informed by root cause analysis of hospital associated thrombosis : 174
Cross-sectional survey of individuals with hepatitis C infection at a UK comprehensive care haemophilia centre : 175
The impact of dabigatran on thrombin generation and other haemostatic markers after orthopaedic surgery : 176
Mutation screening in Glanzmann thrombasthenia: identification of four novel mutations in the ITGA2B and ITGB3 genes : 177
Protein S activity assays. Is it time for laboratories to follow national guidelines? : 178
Thrombin generation test (TGT) in pregnant women at risk of thrombosis on LMWH (low molecular weight heparin): correlation with anti-Xa activity : 179
Evaluation of an external quality assessment material for D-dimer point of care testing kits : 180
Evaluation of efficacy of Orakay and Konakion in the reversal of supra-therapeutic INRs in asymptomatic patients taking warfarin therapy : 181
Fechtner syndrome - a novel mutation : 182
Compound heterozygosity resulting in severe factor XI deficiency : 183
Evaluation of FVIII binding activity in type 2N von Willebrand's disease : 184
Role of fibroscans in the non-invasive investigation of liver fibrosis in haemophiliacs with chronic hepatitis C : 185
Applicability of BCSH guidelines for thrombophilia testing in a UK teaching hospital : 186
Retrospective evaluation of prothrombin complex concentrate usage (Beriplex) in a one year period 2009–10 : 187
MLPA analysis in routine molecular diagnostics - a cautionary tale : 188
Achieving best practice in venous-thromboembolism prophylaxis: the role of audit as an aid to implementation : 189
An audit comparing standards of care for individuals with bleeding disorders in the emergency department to the UKHCDO standards : 190
Usefulness of thromboelastography (TEG) in patients with antiphospholipid antibodies or primary antiphospholipid syndrome : 191
The incidence of venous thromboembolism (VTE) in East London : 192
The use of an electronic patient record to improve patient safety for anticoagulation : 193
Evaluation of fifty patients treated with prothrombin complex concentrate : 194
Healthcare associated venous thromboembolism: difficulties in establishing and monitoring prevalence rates : 195
An audit of decreases in platelet counts and presence of thrombocytopaenia in patients admitted to critical care : 196
Coagulation tests to assess bleeding risk prior to renal biopy : 197
Lepirudin: an appropriately used safe anticoagulant in suspected heparin induced thrombocytopenia? : 198
Outpatient warfarin loading in patients with deep vein thrombosis : 199
From 4% to over 90%: venous thromboembolism risk assessment (VTE RA) in a district general hospital : 200
Audit of coagulation screen requests in acute admissions at a district general hospital : 201
Venous thrombo-embolic risk in pregnancy and the puerperium: can self-assessment identify risk and guide further care? : 202
A comparison of the clinical utility of 2 D-dimer assays in exclusion of suspected pulmonary embolism : 203
Access to routine dental treatment for patients with inherited bleeding disorders : 204
High incident of pseudothrombocytopenia after cardio-pulmonary bypass : 205
A clinical audit into the use of a new venous thromboembolism risk assessment tool in a large tertiary referral hospital in the Belfast Trust : 206
Problems with monitoring heparin in patients with low antithrombin levels : 207
Haemostatic and haemorheological parameters in HIV/Aids patients on antiretroviral therapy : 208
Use of recombinant factor V11 in a district general hospital 2002–2010 : 209
Time to rein in the overuse of the ‘routine’ coagulation screen and reap the financial benefits? : 210
Counting the cost of thrombophilia testing in a district general hospital : 211
Implementing models of care to prevent venous thromboembolism in hospital in-patients: which is the best method? : 212